1-(2-(Azepan-1-yl)ethyl)piperidin-4-amine | 863377-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 1-(2-(Azepan-1-yl)ethyl)piperidin-4-amine
• 英文别名: 1-[2-(azepan-1-yl)ethyl]piperidin-4-amine
• CAS: 863377-25-7
• 化学式: C₁₃H₂₇N₃
• 分子量: 225.377
• InChiKey: VGFAXKCORNQYFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,O-双三甲硅基乙酰胺 、 4-tert-butoxy-2-isopropoxy-7-(R)-oxiranyl-benzothiazole 、 1-(2-(Azepan-1-yl)ethyl)piperidin-4-amine 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 、
  参考文献：
  名称：

  A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of β2-adrenoceptor agonists as inhaled long-acting bronchodilators

  摘要：

  The chiral synthesis of a 4-hydroxybenzothiazolone based series of beta(2)-adrenoceptor agonists is described. Using this methodology a library of N-substituted analogues were prepared for the rapid identification of leads with the potential to be fast onset and long-acting inhaled bronchodilators with improved therapeutic margins. The design of the library to achieve the targeted profile was based upon lipophilicity and metabolism based hypotheses. This approach identified beta-phenethyl, alpha-substituted cyclopentyl and monoterpene N-substituents to be of particular interest for further evaluation, as exemplified by structures 19, 29 and 33, respectively. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.136

文献信息

• [EN] INDOLE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS<br/>[FR] DÉRIVÉS D'INDOLE UTILES EN TANT QU'ANTAGONISTES DE CCR2
  申请人：MERCK SHARP & DOHME

  公开号：WO2012125662A1

  公开（公告）日：2012-09-20

  Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salt thereof wherein R7, A, X, B, and n are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity.

  公开的是公式I的CCR2拮抗剂：I或其药用盐，其中R7、A、X、B和n在此处定义。还公开了含有这些化合物的药物组合物，使用这些化合物的治疗方法，以及用于治疗与CCR2活性相关的疾病或疾病的组合物。
• Chemokine receptor antagonists
  申请人：Hersperger Rene

  公开号：US20070155721A1

  公开（公告）日：2007-07-05

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.

  式(I)的化合物或其药学上可接受的盐或前药酯，其中变体R、R9、Z、X、Q和Y在规范中有定义。
• [EN] CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER AND CARDIOVASCULAR DISEASES<br/>[FR] ANALOGUES DE LA CONOLIDINE SERVANT DE MODULATEURS SÉLECTIFS D'ACKR3 POUR TRAITER LE CANCER
  申请人：LUXEMBOURG INST OF HEALTH LIH

  公开号：WO2022136486A1

  公开（公告）日：2022-06-30

  The present application discloses compounds of e.g. formulae (2), (1A), (1B) or (1C) as selective atypical chemokine receptor 3 (ACKR3) modulators for the treatment of e.g. cancer, atherosclerotic vascular disease, cardiovascular diseases, fibrosis (e.g. cardiac fibrosis), inflammatory or autoimmune diseases and conditions, conditions of excessive or abnormal vascularization (e.g. wound healing), stem cell differentiation and mobilization disorders, brain and neuronal dysfunctions (e.g. Alzheimer's disease, multiple sclerosis and demyelinating diseases), kidney dysfunction, renal dysfunction, preeclampsia, human immunodeficiency virus (HIV) infection and obesity. Further provided are said compounds for use in methods for in vitro or ex vivo diagnosis, prediction, prognosis and/or monitoring of a disease or condition characterized by an aberrant level of ACKR3 polypeptide, as well as for use in in vitro methods for identifying an agent useful as a therapeutic. An exemplary compound is e.g. WW-1.

  本申请公开了化合物的结构公式，如公式（2），（1A），（1B）或（1C），作为选择性非典型趋化因子受体3（ACKR3）调节剂，用于治疗癌症，动脉粥样硬化性血管疾病，心血管疾病，纤维化（例如心脏纤维化），炎症或自身免疫性疾病和病症，过度或异常血管化病症（例如伤口愈合），干细胞分化和移动障碍，脑和神经功能障碍（例如阿尔茨海默病，多发性硬化症和脱髓鞘性疾病），肾功能障碍，肾功能障碍，先兆子痫，人类免疫缺陷病毒（HIV）感染和肥胖症。此外，还提供了这些化合物用于体外或体外诊断、预测、预后和/或监测由ACKR3多肽水平异常特征的疾病或病症的方法，以及用于体外方法，以鉴定作为治疗药物有用的试剂。其中一个示例化合物是WW-1。
• CHEMOKINE RECEPTOR ANTAGONISTS
  申请人：Novartis AG

  公开号：EP1720859B1

  公开（公告）日：2009-12-23
• US7858781B2
  申请人：——

  公开号：US7858781B2

  公开（公告）日：2010-12-28